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Abstract
Background: Simultaneous administration of all age-appropriate doses of vaccines is an 
effective strategy for raising vaccination coverage. Vaccination coverage for ≥4 dose of DTaP 
(diphtheria, tetanus toxoids, and acellular pertussis vaccine) among children 19–35 months in the 
United States has not reached the Healthy People 2020 target of 90%. Risk factors for missed 
opportunities for simultaneous administration of the fourth dose of DTaP have not been 
investigated.
Methods: A missed opportunity for simultaneous administration of the fourth dose of DTaP is 
defined as the failure to administer an age-eligible fourth dose of DTaP, and during the same age-
eligible period for the fourth dose of DTaP other recommended and age-appropriate doses of 
vaccines are given to children. This study used 2001–2014 National Immunization Survey data to 
describe the trend in missed opportunities for simultaneous administration of the fourth dose of 
DTaP from 2001 through 2014, assess the prevalence of children who missed opportunities for 
simultaneous administration of the fourth dose of DTaP by selected factors, and recognize 
significant risk factors for missed opportunities for simultaneous administration of the fourth dose 
of DTaP.
Results: From 2001 to 2014, the prevalence of missed opportunities for simultaneous 
administration of the fourth dose of DTaP among children 19–35 months in the United States 
ranged from 5.7% to 9.0%; across 13 factors considered, the prevalence of missed opportunities 
varied from 3.3% to 22.9%. Children who were late in receiving the first to third dose of DTaP had 
significantly higher prevalence of missed opportunities for simultaneous administration of the 
fourth dose of DTaP than children who received these doses on-time, with adjusted prevalence 
ratios for late vs. on-time of 1.7, 1.6, and 3.2, and all P-value < 0.01.
Conclusions: Improving on-time vaccination of the third dose of DTaP could substantially 
reduce missed opportunities for simultaneous administration of the fourth dose of DTaP.
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1. Introduction
Simultaneous administration of all age-appropriate doses of vaccines has been recommended 
by Advisory Committee on Immunization Practices (ACIP) since 1986, and this 
recommendation is an effective strategy for raising vaccination levels, acquiring and 
sustaining the national objectives of immunization rates among children 19–35 months in 
the United States for all recommended vaccines [1–4]. Simultaneous administration of 
childhood vaccines is defined as administering more than one vaccine on the same visit day, 
at different anatomic sites, and not combined in the same syringe [2]. Vaccination coverage 
studies have demonstrated that one-in-five children falling behind during the interval from 
age 7 months to age 16 months - mostly as a result of missed opportunities for simultaneous 
administration of age-appropriate vaccines [3,5].
Pertussis is a highly contagious respiratory tract bacteria infection. Pertussis incidence has 
been gradually increasing since the early 1980s. A total of 25,827 cases were reported in 
2004, the largest number since 1959, then a total of 27,550 pertussis cases and 27 pertussis-
related deaths were reported in 2010. Case counts of 48,277 from 2012 surpassed 2010 and 
2011. Compared with 2012, the reported cases decreased to 28,639 in 2013, but in 2014 the 
reported cases increased to 32,971 [6]. Large percentage of infected children during recent 
pertussis outbreaks was not vaccinated by choice by their parents, although pertussis 
resurgence has been attributed to waning immunity and other factors, vaccine refusal was the 
primary reason for recent pertussis incidence increasing [7]. The reported pertussis 
incidence (per 100,000 persons) by age group in the United States from 1990 to 2014 has 
shown that infants aged <1 year continue to have the highest reported rate of pertussis, and 
school-aged children 7–10 years continue to contribute a significant proportion of reported 
pertussis cases [8]. Pertussis is a vaccine preventable disease. In order to protect children 
against pertussis, ACIP routingly recommended 4 doses of DTaP (diphtheria, tetanus 
toxoids, and acellular pertussis vaccine) for children in United States [9]. The fourth dose of 
DTaP, recommended at 15–18 months of age, is critical in boosting antibody titers and 
insuring continuous protection [2]. Only small portion of children missed the first, second, 
third dose of DTaP, however many children missed the fourth dose of DTaP [10–17]. About 
15.8% (approximately 1 million) of children in the United States had not received their 
fourth dose of DTaP vaccination in 2014 [18].
Vaccination coverage for ≥4 doses of DTaP among children 19–35 months has not reached 
the 90% target of Healthy People 2020. Missed opportunities for simultaneous vaccinations 
were recognized as one main cause for under vaccination of children, and reducing missed 
opportunities may increase vaccination coverage significantly [5,19]. A recent study 
indicated that if missed opportunities for simultaneous administration of the fourth dose of 
DTaP had been eliminated, the vaccination coverage for ≥4 dose of DTaP could have 
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reached the 90% target of Healthy People 2020 [20]. Missed opportunities for simultaneous 
administration of the fourth dose of DTaP is an important issue on raising immunization rate 
for ≥4 dose of DTaP and protecting children against pertussis, however risk factors for 
missed opportunities for simultaneous administration of the fourth dose of DTaP have not 
been examined.
The immunization information for a large sample of 260,660 children aged 19–35 months in 
the United States has been collected from the 2001–2014 National Immunization Survey 
(NIS) and been applied to this research. This study described the trend in missed 
opportunities for simultaneous administration of the fourth dose of DTaP from 2001 through 
2014, assessed the prevalence of children who missed opportunities for simultaneous 
administration of the fourth dose of DTaP by selected factors, recognized significant risk 
factors for missed opportunities for simultaneous administration of the fourth dose of DTaP 
among 13 selected factors, and determined the adjusted prevalence ratios for missed 
opportunities for simultaneous administration of the fourth dose of DTaP by significant risk 
factors distinguished.
2. Material and methods
2.1. Data resources
CDC started the National Immunization Survey (NIS) in 1994. NIS has been used to 
evaluate vaccination coverage among children 19–35 months in the United States according 
to the immunization schedule recommended by ACIP [9]. The NIS collects immunization 
information through telephone survey of households and mail survey of immunization 
providers. The NIS data collected from 2001 through 2014 were analyzed in this study. 
Detailed descriptions of the 2001–2014 NIS and corresponding response rates have been 
published elsewhere [21].
2.2. Vaccination definition and selected factors
Four doses of DTaP vaccine are recommended by ACIP for children during the first 2 years 
of their life in the United States [9]. By ACIP recommended immunization schedule, the 
children were defined as on-time in receiving the first, second, third dose of DTaP, if 
providers administered the first, second, third dose by 2, 4, 6 months of age to children, 
respectively (i.e., before turning 3, 5, 7 months of age, respectively); or else, the children 
were defined as late in receiving the first, second, third dose of DTaP [17].
In this study, among children who received the first 3 doses of DTaP but missed the fourth 
dose of DTaP, a missed opportunity for simultaneous administration of the fourth dose of 
DTaP is defined as the failure to administer an age-eligible fourth dose of DTaP, and during 
the same age-eligible period for the fourth dose of DTaP other recommended and age-
appropriate doses of vaccines are given to children [22].
The NIS has been collecting immunization data for young children by a varity of socio-
demographic characteristics, such that immunization workers can assess the vaccination 
coverage by those domains, identify groups at risk of low vaccination coverage, and help the 
people in those groups to raise vaccination coverage. Thirteen factors including timeliness of 
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children in receiving the first, second, third dose of DTaP, children heath insurance status, 
and other socio-demographic factors were selected for this risk factor study to explore 
missed the opportunities for simultaneous administration of the fourth dose of DTaP.
2.3. Statistical methods
To implement NIS complex sample survey design into the data analysis of this study, 
SUDAAN 11.0.0 [23] procedures were applied throughout all of the statistical analysis 
process. This study combined 2001–2014 NIS data for the risk factor analysis which could 
reduce sampling errors and correct coverage biases [24]. The trend in missed opportunities 
for simultaneous administration of the fourth dose of DTaP among children in United States 
was assessed by weighted univariate procedure across calendar year of 2001– 2014. 
Weighted categorical data analysis was used to assess the prevalence rates of missed 
opportunities for simultaneous administration of the fourth dose of DTaP vaccine across 
selected factors with combined 2001–2014 NIS data. The NIS weights have been created 
based on the landline and the cell-phone samples. The weighting scheme involves the 
adjustment for household nonresponse, undercoverage of the eligible population, and 
provider non-response. Prevalence ratios were used to evaluate the association of each factor 
with missed opportunities for simultaneous administration of the fourth dose of DTaP. To 
recognize significant factors associated with missed opportunities for simultaneous 
administration of the fourth dose of DTaP, multivariable logistic regression was conducted 
[25]. The adjusted prevalence ratios and associated P-values for each of the factors in the 
final model were reported.
3. Results
3.1. Trend in missed opportunities for simultaneous administration of the fourth dose of 
DTaP from 2001 to 2014
From 2001 to 2014, the prevalence rate of missed opportunities for simultaneous 
administration of the fourth dose of DTaP among children 19–35 months in the United 
States fluctuated from 5.7% to 9.0% with both median and mean of 7.4% (Fig. 1). The 
number of children with missed opportunities for simultaneous administration of the fourth 
dose of DTaP ranged from approximately 340,000–529,000 with median and mean about 
440,000. Prevalence of missed opportunities varied from 5.7% to 9.0% during 2001–2005; 
with less variation, from 7.0% to 8.1%, during the most recent nine years.
3.2. Prevalence of missed opportunities for simultaneous administration of the fourth 
dose of DTaP across selected factors, gained from weighted categorical data analysis, with 
combined 2001– 2014 National Immunization Survey data
Weighted prevalence rates with 95% confidence interval (CI) and weighted prevalence ratios 
(95%CI) for missed opportunities for simultaneous administration of the fourth dose of 
DTaP by selected factors are shown in Table 1. Across all of the factors listed, the prevalence 
rates for missed opportunities for simultaneous administration of the fourth dose of DTaP 
varied from 3.3% to 22.9%. Among the 13 selected factors, the timeliness of the first, 
second, and third dose of DTaP were the factors most strongly associated with prevalence of 
missed opportunities for simultaneous administration of the fourth dose of DTaP. Through 
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the remaining factors, Black non-Hispanic children had the highest prevalence of missed 
opportunities of 9.6%. For children who did not have health insurance, 9.2% experienced 
missed opportunities. Children whose mother was married had significantly lower 
prevalence of missed opportunities, 6.6%, compared to the prevalence rate of 9.0% among 
children whose mother was not married. For children who lived in families below the 
poverty level, approximate 9.3% experienced missed opportunities for simultaneous 
administration of the fourth dose of DTaP. Weighted prevalence ratios for missed 
opportunities for simultaneous administration of the fourth dose of DTaP among categories 
of each factor were statistically significant at P-value < 0.01 level and ranged from 1.2 to 
5.6. Among the 13 factors selected, prevalence ratios were highest for late vs. on-time 
receipt of the first, second, and third dose of DTaP (4.0, 4.8 and 5.6, respectively).
3.3. Factors significantly associated with missed opportunities for simultaneous 
administration of the fourth dose of DTaP, achieved through multivariable analysis, among 
children 19–35 months with combined 2001–2014 National Immunization Survey data
Risk factors significantly associated with missed opportunities for simultaneous 
administration of the fourth dose of DTaP among children 19–35 months in United States 
are shown in Table 2. These independent and significant risk factors are produced through 
multivariable analysis and presented in the final logistic model. In summary, these 7 factors 
could be divided into two risk groups. High risk group is consisted of timeliness of the first, 
second, third dose of DTaP with Adjusted Prevalence Ratio between 1.64 and 3.23. Among 
this high risk group, the timeliness of the third dose of DTaP is the most significantly 
associated with missed opportunities for simultaneous administration of the fourth dose of 
DTaP. Risk of missed opportunities for simultaneous administration of the fourth dose of 
DTaP is about 223% higher among children where the third dose of DTaP is late than in 
children where the third dose of DTaP vaccine is on-time. The low risk group is composed 
of four socio-demographic factors: Family mobility, First born child, Age group of mother, 
and Number of vaccination provider. In this low risk group, the Adjusted Prevalence Ratios 
varied from 1.07 to 1.13.
4. Discussion
Estimates with NIS data from 2001–2014 demonstrated that the published immunization 
rates for ≥4 doses of DTaP in the United States varied from 81.6% to 85.7% which are still 
below the Healthy People 2020 target of 90% level [18,21]. The important meaning for 
reaching that objective has been emphasized in the documents of US Department of Health 
and Human Service (DHHS) and ACIP [4,9]. If providers fully practice simultaneous 
administration of the fourth dose of DTaP, the vaccine uptake for the fourth dose of DTaP 
and further the ≥4 dose of DTaP could be increased significantly [5,19,20]. Our research 
applied this critical policy to 2001– 2014 NIS data, the results of our study shown that the 
fourth dose DTaP uptake might be boosted about 5.7–9.0% which account for about 50% of 
the distance to full vaccination (100%) of ≥4 DTaP, and well enough to catch up the healthy 
people 2020 target; there-fore the immunization rate for ≥4 DTaP will acquire the 90% level 
from 2005 through 2014. Results from our study indicated that the major risk factors 
associated with the missed opportunities for simultaneous administration of the fourth dose 
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of DTaP are late receipt of the first, second, and third dose of DTaP, these three timeliness 
factors are modifiable and it is essential for targeting intervention to these demanding 
components.
According to the ACIP recommendations, licensed combination vaccines can be used 
whenever any components of the combination are indicated [2]. The 4 doses of DTaP series 
may be administered with any FDA licensed single-component vaccines or combination 
vaccines. By the ACIP recommended vaccination schedule, the 1st through the 4th dose of 
DTaP should be administered at 2, 4, 6, 15–18 months age of children with single-
component or combination vaccines. NIS has implemented this ACIP’s policy of 
interchangeability of combination vaccines and single-component vaccines in NIS data 
collection process such as DTaP up-to-date vaccination status, age in months of DTaP 
vaccination, and type of DTaP vaccine. Therefore, the results of this study are applicable to 
any DTaP contained vaccinations for young children in the US. NIS 2001–2014 data shown 
that about 40% of children in the US were administered with single-component vaccine for 
the 4th dose of DTaP.
To improve timeliness of the first 3 doses of DTaP vaccinations, the following suggestions 
could be helpful. Timeliness is the immunization schedule recommended by ACIP, in any 
circumstances physicians and staff must read it carefully, which are the basic and practical 
guides for all of the immunization workers in their efforts to protect children against 
vaccine-preventable diseases, and those schedule should be implemented in physicians and 
staff daily immunization activities. Education of providers to follow the ACIP’s 
recommended immunization schedule rather than something like ‘Alternative Vaccination 
Schedule’. Because the percentage of late in receiving the 3rd dose of DTaP is significantly 
higher than those of late in receiving the 1st and 2nd dose DTaP, in practice the providers 
may need to pay special attention to the timeliness of the 3rd dose of DTaP, and to do 
everything possible to administer the 3rd dose of DTaP on-time at age of 6 months. Use 
client reminder and recall interventions to remind members of a target population that 
vaccinations are due (reminders) or late (recall), which has been established to be the 
effective interventions in immunization practice [26].
In this study, we analyzed missed opportunities for simultaneous administration of the fourth 
dose of DTaP among children who received the first 3 doses of DTaP but missed the fourth 
dose of DTaP. Therefore, vaccine hesitancy may be one factor associated with missed 
opportunities for simultaneous administration of the fourth dose of DTaP. It is rather difficult 
to categorize a population-group as vaccine-hesitant accurately, however immunization 
workers have realized that there is an increasing trend toward vaccine hesitancy [27]. 
Different tools and ways have been developed to counter vaccine hesitancy. Education of 
vaccine-hesitant parents might be one effective intervention which should pay special 
attention to improve parent’s confidence in the value of vaccines including the following 
topics: “Vaccines are necessary to protect the health of children”, “If I do not vaccinate my 
child, he/she may get a disease and cause other children or adults also to get the disease”, 
and “Vaccine are safe” [28]. Education of parents by addressing those questions may reduce 
parents’ vaccine hesitancy, enhance parents’ vaccine acceptance. Thus parents could be 
willing to bring their children to receive the 4 doses of DTaP vaccination on-time, and 
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further to reduce the missed opportunities for simultaneous administration of the fourth dose 
of DTaP vaccine.
Our research possessed several restrictions. First, this study solely accounted for the 
vaccination visits in our hunting for missed opportunities for simultaneous administration of 
the fourth dose of DTaP. However, in real life, many missed opportunities may exist in the 
process of parents who seek child health care, for example well child visits, screening visits, 
annual visits etc. Consequently, in this research missed opportunities for simultaneous 
administration of the fourth dose of DTaP might be underestimated [22]. Second, landline 
telephone survey design was utilized to sample household in early years of NIS, later years 
of NIS adopted dual-frame strategy in data collection process. Thus survey non-coverage 
could have negative impact on the results of our study. Nevertheless, latest publications in 
peer-reviewed journals suggested that the potential bias in estimates of missed opportunities 
for simultaneous administration of the fourth dose of DTaP vaccine resulting from not 
sampling households with cell phone service might be small [18,29–31].
5. Conclusions
This study suggests that the timeliness in receiving the first, second, and third dose of DTaP 
vaccine are significant and potentially modifiable risk factors for missed opportunities for 
simultaneous administration of the fourth dose of DTaP. Encouraging providers to deliver all 
recommended vaccines that are due at each visit might decrease missed opportunities for 
simultaneous administration of the fourth dose of DTaP. Future interventions focusing on the 
group of late in receiving the third dose of DTaP could substantially eliminate missed 
opportunities for simultaneous administration of the fourth dose of DTaP, further to increase 
≥4 DTaP vaccination coverage level, and reduce pertussis infection among children in the 
United States.
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Fig. 1. 
Trend in missed opportunities in percentage (%) with 95% confidence interval (CI) for 
simultaneous administration of the fourth dose of DTaPa among children 19–35 months in 
the United States, National Immunization Survey, 2001–2014. a Diphtheria and Tetanus 
toxoids and acellular Pertussis.
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